Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab versus triamcinolone for treatment and prevention of frequent gout flares
2010-024172-26Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of canakinumab in gout (2 arms), sponsored by Novartis. Primary endpoint: Co-primary objectives. Started Aug 2011; status: completed.
02
Drugs
canakinumab
03
Conditions
gout
Beyond the preview
Go deeper on 2010-024172-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024172-26.